Medina-Vicent NA, Ruiz-Esmenjaud J, Arenas-Guzmán R

Language: Spanish
References: 24
Page: 50-56
PDF size: 256.39 Kb.

ABSTRACT

Porokeratosis are a group of dermatoses characterized by a disorder of keratinization secondary to a clonal expansion of keratinocytes. They have a very varied clinical presentation, localized, disseminated and even eruptive forms. Histopathological diagnosis can be confirmed by the presence of the cornoid lamella. Porokeratosis has been associated with immunosuppression, ultraviolet radiation, systemic, infectious and neoplastic diseases. It is also considered a premalignant entity given its potential for neoplastic degeneration, mainly to squamous cell and basal cell carcinoma. Currently there is not an adequate therapeutic option.

REFERENCES

1. Vargas-Mora P, Morgado-Carrasco D y Fustà-Novell X, Porokeratosis:a review of its pathophysiology, clinical manifestations, diagnosis,and treatment, Actas Dermosifiliogr 2020; 111(7):545-60. doi: 10.1016/j.ad.2020.03.005.

2. Das A, Vasudevan B y Talwar A, Porokeratosis: an enigma beginningto unravel, Indian J Dermatol Venereol Leprol 2022;88(3):291-9.

3. Inci R, Zagoras T, Kantere D, Holmström P, Gillstedt M, Polesie Sy Peltonen S, Porokeratosis is one of the most common genodermatosesand is associated with an increased risk of keratinocytecancer and melanoma, J Eur Acad Dermatol Venereol2023; 37(2):420-7. doi: 10.1111/jdv.18587.

4. Yeh JE, Nazarian RM y Lorenzo ME, Treatment of porokeratosisof Mibelli with combined use of topical fluorouracil andcalcipotriene, jaad Case Rep 2021; 23(9):54-56. doi: 10.1016/j.jdcr.2021.01.012.

5. Le C y Bedocs PM, Disseminated superficial actinic porokeratosis2022, 8, Treasure Island, FL, StatPearls Publishing, 2023.

6. Shen C-S, Tabata K, Matsuki M, Goto T, Yokochi T y YamanishiK, Premature apoptosis of keratinocytes and the dysregulationof keratinization in porokeratosis, Br J Dermatol 2002;147(3):498-502. Disponible en: http://dx.doi.org/10.1046/j.1365-2133.2002.04853.x.

7. Kanitakis J, Porokeratoses: an update of clinical, aetiopathogenicand therapeutic features, Eur J Dermatol 2014; 24(5):533-44.doi: 10.1684/ejd.2014.2402.

8. Kim DS, Roh MR, Lee JH y Lee KH, Pterygium unguis formationin porokeratosis of Mibelli, Br J Dermatol 2007; 156(6):1384-5.doi: 10.1111/j.1365-2133.2007.07887.x.

9. Loughlin CR y Podlipnik S, Porokeratosis of Mibelli, DermatolPract Concept 2020; 26,10(4):e2020112. doi: 10.5826/dpc.1004a112.

10. Silva L y Pimentel BV, Visual dermatology: porokeratosis of Mibelli,J Cutan Med Surg 2020; 24(6):639. doi: 10.1177/1203475420928910.

11. Valdivieso-Ramos M, Poroqueratosis genital, Actas Dermosifiliogr2008; 99(3):217-20. doi: 10.1016/s0001-7310(08)74659-3.

12. Deane L, Poroqueratosis: revisión, Rev Argent Dermatol 2012; 93(4).Disponible en: http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid= S1851-300X2012000400010&lng=es.

13. Contreras-Ruiz J, Toussaint-Caire S, Torres-Camacho P y Villa-CastroVB, Porokeratosis ptychotropica: a diagnostic and therapeuticchallenge, J Eur Acad Dermatol Venereol 2018; 32(3):e114-5. Disponibleen: http://dx.doi.org/10.1097/PAT.0000000000000285.

14. Kim J, Andrew Wood B y Harvey NT, Follicular porokeratosis ofthe nose: two further cases of an emerging variant of porokeratosis,Pathology 2015; 47(5):482-5. Disponible en: http://dx.doi.org/10.1097/pat.0000000000000285.

15. Joshi R y Minni K, Genitogluteal porokeratosis: a clinical review,Clin Cosmet Investig Dermatol 2018; 1(11):219-29. doi: 10.2147/CCID.S143085.

16. Ou X, Wang P, Chen W, Wu W y Lu J, A case report of porokeratosisptychotropica in a Chinese man, Clin Cosmet InvestigDermatol 2021; 7(14):1449-51. doi: 10.2147/CCID.S334682.

17. Buhle AC, Fagan KK, Johnson NM y Grider DJ, Treating linearporokeratosis with topical lovastatin/cholesterol cream, DermatolOnline J 2022; 15(28):5. doi: 10.5070/D328559247. PMID:36809136.

18. Weidner T, Illing T, Miguel D y Elsner P, Treatment of porokeratosis:a systematic review, Am J Clin Dermatol 2017; 18(4):435-49. doi: 10.1007/s40257-017-0271-3.

19. Raychaudhury T y Valsamma DP, Giant porokeratosis, Indian JDermatol Venereol Leprol 2011; 77(5):601-2. doi: 10.4103/0378-6323.84072.

20. Waqar MU, Cohen PR y Fratila S, Disseminated superficial actinicporokeratosis (dsap): a case report highlighting the clinical,dermatoscopic, and pathology features of the condition, Cureus2022; 14(7):e26923. doi: 10.7759/cureus.26923.

21. Ho T, Schwentker AR, Barron DR y Lucky AW, Clinical courseof porokeratosis ptychotropica over 7 years in an otherwisehealthy child, Pediatr Dermatol 2020; 37(1):248-50. doi: 10.1111/pde.

22. Weidner T, Illing T, Miguel D et al., Treatment of porokeratosis:a systematic review, Am J Clin Dermatol 2017; 18:435-49. Disponibleen: https://doi.org/10.1007/s40257-017-0271-3.

23. Skupsky H, Skupsky J y Goldenberg G, Disseminated superficialactinic porokeratosis: a treatment review, J DermatologTreat 2012; 23(1):52-6. doi: 10.3109/09546634.2010.495381.

24. Sertznig P, Von Felbert V y Megahed M, Porokeratosis: presentconcepts, J Eur Acad Dermatol Venereol 2012; 26(4):404-12.doi: 10.1111/j.1468-3083.2011.04275.x.